ライフサイエンスコーパス: neuroendocrine

1 it has become evident that there is possible neuroendocrine action of estrogen receptor alpha (ERalph

2 n active, coping behaviors while restraining neuroendocrine activation to optimize adaptation during

3 growth hormone (GH) signaling also promotes neuroendocrine adaptations during food deprivation.

4 Our investigations of this phenomenon in neuroendocrine adrenal chromaffin cells show that a sing

5 sms, with a focus on cytokine responses, the neuroendocrine and autonomic pathways that connect sleep

6 n of lamina terminalis AT1aR neurons induces neuroendocrine and behavioral responses that increase bl

7 at different gestational ages, consisting of neuroendocrine and cortical components and expressing th

8 leptin signaling cause permanent metabolic, neuroendocrine and developmental problems.

9 ations, offering insight into the origins of neuroendocrine and exocrine tumors.

10 n profiles for signaling cascades related to neuroendocrine and inflammatory functions differ among t

11 SCLC cells normally express neuroendocrine and neuronal gene programs but accumulati

12 ytosolic factor involved in the formation of neuroendocrine and neuronal granules.

13 e environmental changes to elicit downstream neuroendocrine and physiological responses are just star

14 and are able to differentiate into luminal, neuroendocrine, and basal cells.

15 egrate negative emotions with the autonomic, neuroendocrine, and immune systems to facilitate respons

16 lls become relatively more neuronal and less neuroendocrine as they gain the ability to metastasize.

17 Multiple neuroendocrine, autonomic and behavioral responses are r

18 Our data establish an immune-neuroendocrine axis in calibrating rapid 5-HT release fo

19 , Aplysia californica, synaptic input to the neuroendocrine bag cell neurons triggers various cation

20 ethodological framework for the study of the neuroendocrine basis of female social aggression and dom

21 many animals, yet little is known about the neuroendocrine basis of nursing in non-mammalian species

22 tant prostate tumors often display neural or neuroendocrine behavior.

23 the solitary tract (NTS) where it initiates neuroendocrine, behavioral, and autonomic reflex respons

24 Neuroendocrine biomarker levels did not predict treatmen

25 Methods: Neuroendocrine biomarker profiles (progastrin-releasing

26 Results: Neuroendocrine biomarker profiles were abnormal in most

27 We investigated the effect of circulating neuroendocrine biomarkers on the efficacy of prostate-sp

28 /WDR7 colocalize with CAPS1 on DCVs in human neuroendocrine (BON) cells.

29 s in a spontaneous mouse model of pancreatic neuroendocrine cancer (PanNET), RIP1-Tag2.

30 therapy, we demonstrate that mouse models of neuroendocrine cancer are responsive to selective Cdk5 i

31 all cell lung cancer (SCLC) is an aggressive neuroendocrine cancer characterized by initial chemosens

32 oliferation and metastasis during pancreatic neuroendocrine cancer development.

33 Merkel cell carcinoma (MCC)-a neuroendocrine cancer of the skin-is caused by the integ

34 tumor was consistent with a 59 mm small cell neuroendocrine cancer with a Ki-67 index of 80%.

35 Small-cell neuroendocrine cancers (SCNCs) are an aggressive cancer

36 tical used in the diagnosis and treatment of neuroendocrine cancers.

37 patients with metastatic breast, kidney, and neuroendocrine cancers.

38 in the chlorambucil plus obinutuzumab group (neuroendocrine carcinoma of the skin).

39 cell carcinomas (MCCs), a highly aggressive neuroendocrine carcinoma of the skin.

40 toxicity in small-cell lung cancer (SCLC), a neuroendocrine carcinoma with high mortality and modest

41 Poorly differentiated anal neuroendocrine carcinomas (ANECs) are rare lesions with

42 a GNET Type 3: 1 well-differentiated NET G3, neuroendocrine carcinomas (NECs) (n = 3), and controls (

43 s with EGFR-mutant SCLC and other high-grade neuroendocrine carcinomas seen at our eight institutions

44 fluid (BALF) would distinguish children with neuroendocrine cell hyperplasia of infancy (NEHI), surfa

45 with regard to the expression of AR and the neuroendocrine cell markers Synaptophysin and Chromogran

46 Pulmonary neuroendocrine cells (PNECs) are rare airway epithelial

47 % of lung progenitor cells to form pulmonary neuroendocrine cells (PNECs), putative precursors to sma

48 are the likely progenitor of both pulmonary neuroendocrine cells and CFTR-rich ionocytes.

49 These neuroendocrine cells are uniquely identifiable and amena

50 onooxygenase (PAM) is an enzyme expressed by neuroendocrine cells that participates in hormone matura

51 se that KIN-29/SIK acts in nuclei of sensory neuroendocrine cells to transduce low cellular energy ch

52 oves the description of ionocytes, pulmonary neuroendocrine cells, and brush cells and identifies a r

53 nerves, PNECs, as prototype tissue-resident neuroendocrine cells, are at the center of a neuro-immun

54 In neuroendocrine cells, MYC activates Notch to dedifferent

55 supraoptic nucleus, consisting primarily of neuroendocrine cells, which are persistently and commonl

56 ing the effect of FTY-720 on the survival of neuroendocrine cells.

57 ration in isolated vesicles from neurons and neuroendocrine cells.

58 dent ERK->Egr-1/Zif268 signaling in cultured neuroendocrine cells; in D1 medium spiny neurons of NAc

59 e regulatory network specifies the ancestral neuroendocrine center of animals and the apical organ of

60 ting neural cells from an ancestral anterior neuroendocrine center.

61 by melatonin binding in vocal, auditory, and neuroendocrine centers.

62 sphingosine analogue enhances exocytosis in neuroendocrine chromaffin cells, altering the quantal re

63 A wealth of specialized neuroendocrine command systems intercalated within the h

64 therapies for neurological, neuro-immune and neuroendocrine conditions.

65 uture when integrating with well-established neuroendocrine control of excretion.

66 l endocrine disruption, resulting in altered neuroendocrine control of hormonal signaling, altered ne

67 Recent findings have indicated that the neuroendocrine control of puberty may be regulated by a

68 ellent model to study rapid fluid transport, neuroendocrine control of renal function, and modeling o

69 years suggests that the organization of the neuroendocrine control of reproduction is also sensitive

70 ) to representative EDCs with a focus on the neuroendocrine control of reproduction, pubertal timing

71 nsformation of adenocarcinomas to aggressive neuroendocrine derivatives - was initially described in

72 ration-resistant prostate cancer (CRPC) with neuroendocrine differentiation (NED) is a lethal disease

73 rans-differentiation process, referred to as neuroendocrine differentiation (NED).

74 ult in some adverse effects via inducing the neuroendocrine differentiation (NED).

75 (high) luminal cells are more predisposed to neuroendocrine differentiation along passaging and are r

76 iagnostic information by unmasking an occult neuroendocrine differentiation and identifying a misclas

77 unctioning as a transcriptional repressor in neuroendocrine differentiation and is activated by N-Myc

78 Genetic ablation of Sox2 suppresses neuroendocrine differentiation but does not impact the c

79 e found that KDM5A sustains ASCL1 levels and neuroendocrine differentiation by repressing NOTCH2 and

80 ary and sufficient to induce prostate cancer neuroendocrine differentiation in a paracrine manner.

81 Neuroendocrine differentiation is associated with treatm

82 nsistently, FOXB2 controls Wnt signaling and neuroendocrine differentiation of prostate cancer cell l

83 2 is necessary for androgen ablation-induced neuroendocrine differentiation of Pten null prostate ade

84 This study demonstrates de novo neuroendocrine differentiation of the human prostate lum

85 nocking down TACSTD2 and SOX2 both attenuate neuroendocrine differentiation of tumor organoid cells.

86 KDM5A promotes SCLC proliferation and SCLC's neuroendocrine differentiation phenotype in part by sust

87 Prostate adenocarcinoma undergoes neuroendocrine differentiation to acquire resistance tow

88 more inclined to develop castration-induced neuroendocrine differentiation.

89 Here, we show that, during lactation, neuroendocrine dopamine neurons, the "TIDA" cells that c

90 CNSDS induces chronic stress behavioral and neuroendocrine effects in both male and female C57BL/6J

91 t expression, AR transcriptional output, and neuroendocrine expression signatures, with clinical outc

92 ating food consumption and AgRP2 acting as a neuroendocrine factor regulating the stress axis.

93 arcinoma features (CRPC-adeno) vs those with neuroendocrine features (CRPC-NE).

94 owth and metastatic colonization and reverse neuroendocrine features in Trop2-driven NEPC.

95 nesis is likely to induce the characteristic neuroendocrine features of MCC via induction of ATOH1; t

96 apture certain aspects of the behavioral and neuroendocrine features of MDD, the extent to which they

97 shown to directly generate tumor cells with neuroendocrine features when transduced with oncogenic s

98 onneuronal endothelial cells into cells with neuroendocrine features.

99 Thus, adult C. elegans males employ a neuroendocrine feedback loop that integrates food detect

100 Here, we identify a neuroendocrine feedback loop that sex-specifically regul

101 neurohumoral signals to coordinate behavior, neuroendocrine function, and autonomic function.

102 s NaCl-sensitive neurons to regulate thirst, neuroendocrine function, and autonomic outflow.

103 communications involved in the regulation of neuroendocrine functions.

104 peptide precursor protein that has critical neuroendocrine functions; however, its role in the kidne

105 Test may reflect early evidence of increased neuroendocrine gene expression of hypergastrinemia-induc

106 t of shared glutamatergic, dopaminergic, and neuroendocrine genetic variation in aggression and CU-tr

107 embryonic development of the pineal organ, a neuroendocrine gland on top of the diencephalon, remains

108 tem and defective embryonic migration of the neuroendocrine GnRH cells to the basal forebrain, which

109 orspheroidal growth, that is, resembling the neuroendocrine growth pattern of classical MCC cell line

110 ions are enriched in metastatic tumours with neuroendocrine histology.

111 Serotonin (5HT) is a neuroendocrine hormone synthetized in the central nervou

112 crinology and argue that greater emphasis on neuroendocrine human skin research will foster the devel

113 Although the behavioral and neuroendocrine impacts of social buffering are well stud

114 anism for integrating multiple endocrine and neuroendocrine inputs to control hepatic glucose product

115 hemosensory neurons, resulting in diminished neuroendocrine insulin signaling that extends the durati

116 rated capillaries in the hypophysis, a major neuroendocrine interface between the blood and brain.

117 -old woman (body mass index: 18.5 kg/m) with neuroendocrine liver metastases of a digestive origin un

118 ocal adipose-SNS relationship comprising the neuroendocrine loop facilitated primarily by adipose tis

119 Here we describe murine models of high-grade neuroendocrine lung carcinomas generated by the loss of

120 therapy is a rational treatment approach for neuroendocrine malignancies.

121 as had a significant impact on management of neuroendocrine malignancies.

122 gan metastasis, suppressing AR, and inducing neuroendocrine marker mRNAs.

123 Conclusion: Neuroendocrine marker profiles do not predict an adverse

124 fic antigen response in relation to baseline neuroendocrine marker profiles.

125 h KDM8 and EZH2 are further elevated, so are neuroendocrine markers.

126 1360780 genotype, FKBP5 gene expression, and neuroendocrine measures) with offspring FKBP5 methylatio

127 A growing appreciation of the overlapping neuroendocrine mechanisms controlling energy balance has

128 KS lesion cells exhibit many similarities to neuroendocrine (NE) cancers, such as highly vascular and

129 Pulmonary neuroendocrine (NE) cells are neurosensory cells sparsel

130 adenocarcinoma cells transdifferentiate into neuroendocrine (NE) cells to escape potent anti-androgen

131 Neuroendocrine (NE) differentiation is a well-recognized

132 the adenocarcinoma phenotype transforms into neuroendocrine (NE) disease.

133 expression of genes related to neuronal and neuroendocrine (NE) functions that are characteristic of

134 well-characterized androgen receptor (AR) or neuroendocrine (NE) genes: (i) AR-high tumors (ARPC), (i

135 ent of domains and cellular abundance in the neuroendocrine (NE) microenvironment.

136 n is an established technique for staging of neuroendocrine neoplasia and determining the suitability

137 a prospective trial, 10 patients with known neuroendocrine neoplasia and positive for uptake on (68)

138 vealed a cytokeratin 20-positive, high-grade neuroendocrine neoplasm consistent with Merkel cell carc

139 tudinally in an orthotopic murine pancreatic neuroendocrine neoplasm model expressing human SSTR2.

140 expression of somatostatin receptors on this neuroendocrine neoplasm opened up the opportunity to tre

141 ational cohort of resected cystic pancreatic neuroendocrine neoplasms (cPanNENs) and identify preoper

142 The characteristics of cystic pancreatic neuroendocrine neoplasms (cPanNENs) are largely unknown,

143 ed utility of the NETest to diagnose gastric neuroendocrine neoplasms (GNENs) and identify micro- and

144 Neuroendocrine neoplasms (NENs) are rare epithelial tumo

145 Accurate grading of patients with neuroendocrine neoplasms (NENs) is essential for risk st

146 atostatin receptors (SSTRs) in patients with neuroendocrine neoplasms (NENs) is used for both diagnos

147 radionuclide therapy (PRRT) of grade 3 (G3) neuroendocrine neoplasms (NENs) with a Ki-67 proliferati

148 ellent for lesion detection in patients with neuroendocrine neoplasms (NENs).

149 een demonstrated, mainly in the treatment of neuroendocrine neoplasms by using (177)Lu-labeled somato

150 rt that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids in

151 ymic epithelial tumours, and other pulmonary neuroendocrine neoplasms) and a COVID-19 diagnosis, eith

152 is an effective treatment for patients with neuroendocrine neoplasms.

153 TR) analogs is a common approach in advanced neuroendocrine neoplasms.

154 subgroups of patients with multiple types of neuroendocrine neoplasms.

155 hypothalamic-pituitary-adrenal (HPA) axis, a neuroendocrine network that controls hormonal responses

156 d females with a focus on vocal-acoustic and neuroendocrine networks.

157 ural anesthesia (OR 1.59, 95% CI 1.17-2.16), neuroendocrine or nonmalignant pathology (OR 1.56, 95% C

158 pituitary glands, and suggests that all CNS neuroendocrine organs may require a non-neural contribut

159 vident, and immunohistochemistry supported a neuroendocrine origin.

160 an inner catecholamine-producing medulla of neuroendocrine origin.

161 -Sema4D antibodies in a preclinical model of neuroendocrine pancreatic cancer (Rip1-Tag2), mediated b

162 Neuroendocrine pathway genes are upregulated by intestin

163 These studies suggest a potential role of neuroendocrine pathway genes in the pathobiological char

164 e relevance of pathological altruism and the neuroendocrine pathways associated with hostile behavior

165 Modulation of these neuroendocrine pathways by intestinal infection serves a

166 c target for metastatic prostate cancer with neuroendocrine phenotype and suggest that high Trop2 lev

167 ive states via phenotype switching towards a neuroendocrine phenotype or acquisition of stem-like pro

168 , drives prostate cancer growth, and induces neuroendocrine phenotype.

169 NOTCH pathway activation and repression of a neuroendocrine phenotype.

170 ological stress response systems and related neuroendocrine processes may function as plasticity mech

171 time, or delayed) may be governed by similar neuroendocrine processes.

172 These cortical and neuroendocrine progenitor cells retain in vitro an intri

173 Cysts showed monomorphic neuroendocrine proliferation and lined by ductal epithel

174 arcinoma histology to a castration-resistant neuroendocrine prostate cancer (CRPC-NE).

175 ggressive androgen receptor (AR)-independent neuroendocrine prostate cancer (NEPC) after androgen-dep

176 eptor (AR) signaling-independent and develop neuroendocrine prostate cancer (NEPC) features through l

177 Neuroendocrine prostate cancer (NEPC) is an aggressive m

178 Neuroendocrine prostate cancer (NEPC) is an aggressive v

179 Neuroendocrine prostate cancer (NEPC) is thought to aris

180 fests in a partial or complete small cell or neuroendocrine prostate cancer (NEPC) phenotype.

181 ormonal therapies have led to an increase of neuroendocrine prostate cancer (NEPC), a highly aggressi

182 Neuroendocrine prostate cancer (NEPC), a lethal form of

183 Therapy-induced neuroendocrine prostate cancer (NEPC), an extremely aggr

184 have paradoxically promoted the incidence of neuroendocrine prostate cancer (NEPC), the most lethal s

185 bon (SGOC) metabolic network is required for neuroendocrine prostate cancer, a castration-resistant a

186 The mathematical model demonstrated that neuroendocrine, protein kinase C-theta, and triggering r

187 Dopaminergic, glutamatergic, and neuroendocrine PRS showed evidence of association with u

188 xpress Slc17a6/Vglut2) and are distinct from neuroendocrine PVH neurons.

189 KS patient tissues and the heterogeneity of neuroendocrine receptors having opposing roles in KSHV-i

190 Galanin (Gal) is a peptide with a role in neuroendocrine regulation of the liver.

191 is, we demonstrate that pre-optic AgRP2 is a neuroendocrine regulator of the stress axis that reduces

192 s (HPA axis, immuno-inflammatory activation, neuroendocrine regulators of energy metabolism including

193 une signals participate in gut sensation and neuroendocrine response remains unclear.

194 currently known about sex differences in the neuroendocrine response to stress, as well as outstandin

195 ffect health directly, through autonomic and neuroendocrine responses, but also indirectly, through c

196 iliary, cervical, endometrial, mesothelioma, neuroendocrine, salivary, small-cell lung, thyroid, and

197 the primary tumor in metastatic small bowel neuroendocrine (SB-NET) remains controversial.

198 inflammation and disrupted energy-regulating neuroendocrine signaling (e.g., leptin, insulin).

199 rotonergic, dopaminergic, glutamatergic, and neuroendocrine signaling pathways.

200 face characterized 53% of pathways including neuroendocrine signaling, calcium signaling, triggering

201 dynamic relationships among stress exposure, neuroendocrine signaling, inflammation, and mitochondria

202 e of microbes and modulate host behavior via neuroendocrine signaling.

203 the antiviral NK cell response by adrenergic neuroendocrine signals.

204 cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer with steadily increasing inci

205 on, changes social preference, and increases neuroendocrine stress responses in male mice, while the

206 luding medial-prefrontal cortical circuitry, neuroendocrine stress responses, homeostatic energy regu

207 framework for understanding the reproductive neuroendocrine system and opens new horizons for fertili

208 tenance of chronic pain are regulated by the neuroendocrine system and, specifically, sensory neurona

209 tural sleep and reveal a crucial role of the neuroendocrine system in regulating global brain states.

210 ponse to octopamine, uncovering a regulatory neuroendocrine system in the developmental transition fr

211 In response to injury, the neuroendocrine system increases secretion of counterregu

212 ta shed light on how spiking patterns in the neuroendocrine system translate to vesicular release tow

213 ss of signaling molecules in the nervous and neuroendocrine system, but they are challenging to study

214 ddress this issue in dopamine neurons of the neuroendocrine system, which faces particular spatiotemp

215 The functions of nervous and neuroendocrine systems rely on fast and tightly regulate

216 targeted effects on vocal motor, sensory and neuroendocrine systems; are unique from nonapeptide-expr

217 Additionally, 8%, 49% and 75% of neuroendocrine TH, TRH and CRH neurons, and 67%, 32% and

218 type in part by sustaining expression of the neuroendocrine transcription factor ASCL1.

219 ferentiation and activated a mesenchymal and neuroendocrine transcriptional program.

220 s of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, which results in re

221 sion and therapy resistance, with a focus on neuroendocrine transformation in lung and prostate tumou

222 -standing controversy about the existence of neuroendocrine transmitter reuptake.

223 N) resection after appendectomy for appendix neuroendocrine tumor (A-NET) remain controversial, espec

224 ovel multi-gene liquid biopsy has utility in neuroendocrine tumor (NET) diagnosis and identification

225 tide receptor radionuclide therapy (PRRT) in neuroendocrine tumor (NET) patients treated with (90)Y-D

226 tide receptor radionuclide therapy (PRRT) in neuroendocrine tumor (NET) patients treated with (90)Y-D

227 The incidence of pancreatic neuroendocrine tumor (PNET) is increasing, and it presen

228 of the gastrointestinal tract and low grade neuroendocrine tumor as part of the TSC syndromic phenot

229 l carcinoma was first described in 1972 as a neuroendocrine tumor of skin, most cases of which were r

230 MCC is a rare, clinically aggressive neuroendocrine tumor of the skin with a high propensity

231 Methods: PRRT-naive adult neuroendocrine tumor patients with liver-dominant metast

232 en the high frequency of liver metastases in neuroendocrine tumor patients, we aimed to determine whe

233 According to the European NeuroEndocrine Tumor Society (ENETS) recommendations, 85

234 Representatives from the North American Neuroendocrine Tumor Society and the Society of Nuclear

235 Methods: Using PRRT databases at 2 European Neuroendocrine Tumor Society Centers of Excellence, case

236 umor diameter-based algorithm for pancreatic neuroendocrine tumor surveillance may potentially reduce

237 Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single dise

238 cessive overproduction of calcitriol by this neuroendocrine tumor was the cause of the refractory hyp

239 trasound guided biopsy revealed a pancreatic neuroendocrine tumor with multifocal liver metastases, s

240 ncy due to a calcitriol-producing pancreatic neuroendocrine tumor, responding to peptide receptor rad

241 on-induced hypercalcemia due to a pancreatic neuroendocrine tumor.

242 othesis of a calcitriol producing pancreatic neuroendocrine tumor.

243 othesis of a calcitriol-producing pancreatic neuroendocrine tumor.

244 s: gastrointestinal polyposis and pancreatic neuroendocrine tumor.

245 the characterization of gastroendopancreatic neuroendocrine tumors (GEP-NET).

246 lished prognostic factor in gastrointestinal neuroendocrine tumors (GI-NETs) and defines tumor grade.

247 vival benefit in metastatic gastrointestinal neuroendocrine tumors (GI-NETs); however, few studies ha

248 iliary malignancies including non-viral HCC, neuroendocrine tumors (NET), and colorectal carcinoma wi

249 Patients with neuroendocrine tumors (NETs) are often treated with soma

250 related to nodal involvement in appendiceal neuroendocrine tumors (NETs), to identify patients who s

251 sted for therapy monitoring in patients with neuroendocrine tumors (NETs).

252 sembles other types of poorly differentiated neuroendocrine tumors (NETs).

253 to characterize gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).

254 s with somatostatin receptor (SSTR)-positive neuroendocrine tumors (NETs).

255 Derived from endocrine cells, pancreatic neuroendocrine tumors (PanNET) universally hypersecrete

256 al adenocarcinoma (PDAC, n = 58), pancreatic neuroendocrine tumors (PanNET, n = 42), intraductal papi

257 ular alterations in small primary pancreatic neuroendocrine tumors (PanNETs) associated with the deve

258 Most pancreatic neuroendocrine tumors (PNETs) do not produce excess horm

259 ning parameters for patients with pancreatic neuroendocrine tumors (PNETs; 124 patients and 381 scans

260 Patients with small intestinal neuroendocrine tumors (SI-NETs) frequently develop sprea

261 mes of primary tumor resection in metastatic neuroendocrine tumors across all primary tumor sites.

262 f (67)Cu-CuSarTATE in a preclinical model of neuroendocrine tumors and compare it with the standard P

263 n the biochemical diagnosis and follow-up of neuroendocrine tumors and inborn errors of metabolism.

264 The UPR is upregulated in pancreatic neuroendocrine tumors and its inhibition significantly r

265 or organs at risk (OARs) in the treatment of neuroendocrine tumors and meningioma.

266 afe treatment for patients with metastasized neuroendocrine tumors and prostate cancer, and the occur

267 or different radiopharmaceuticals applied to neuroendocrine tumors and prostate cancer.

268 on several types of solid tumors, including neuroendocrine tumors and small-cell lung cancer.

269 hough up to 30-40% of gastroenteropancreatic neuroendocrine tumors are known to be functional (i.e. p

270 Gastroenteropancreatic neuroendocrine tumors are relatively rare neoplasms, cha

271 e secreted), calcitriol secreting pancreatic neuroendocrine tumors are very rare.

272 al biology screen and identified a subset of neuroendocrine tumors displaying a striking pattern of s

273 may be useful when stratifying patients with neuroendocrine tumors in future trials.

274 te that the similarity of KS lesion cells to neuroendocrine tumors is probably a result of KSHV infec

275 prognostic tool stratifies patients with GEP neuroendocrine tumors receiving SSA treatment according

276 similarity of KS lesion endothelial cells to neuroendocrine tumors remains unknown.

277 ion was 0.85, which was higher than European Neuroendocrine Tumors Society/American Joint Committee o

278 ds: Data were available for 10 patients with neuroendocrine tumors treated with (177)Lu-DOTATATE and

279 Treatment of neuroendocrine tumors with (177)Lu-octreotate results in

280 nically approved agents for the treatment of neuroendocrine tumors, neuroblastoma, and non-Hodgkin ly

281 d DOTATATE peptides, which are used to image neuroendocrine tumors, predict treatment response, and t

282 analogs is a well-established treatment for neuroendocrine tumors, with (177)Lu-DOTATATE having acqu

283 atment of somatostatin receptor 2-expressing neuroendocrine tumors.

284 eatment for somatostatin receptor-expressing neuroendocrine tumors.

285 reatment for advanced gastroenteropancreatic neuroendocrine tumors.

286 tment for somatostatin receptor 2-expressing neuroendocrine tumors.

287 ients with metastatic gastroenteropancreatic neuroendocrine tumors.

288 (LC) are rare and slow growing primary lung neuroendocrine tumors.

289 ty of (177)Lu-DOTATATE in humans affected by neuroendocrine tumors.

290 ospective dosimetry tool in 10 patients with neuroendocrine tumors.

291 for the treatment of neuroblastoma and other neuroendocrine tumors.

292 are overexpressed in neuroblastoma and other neuroendocrine tumors.

293 h somatostatin receptor-2 (SSTR2)-expressing neuroendocrine tumour (NET) though tumour regression occ

294 peptide receptors and is typically used for neuroendocrine tumours (NETs).

295 In advanced stages, AIG might progress to neuroendocrine tumours and gastric adenocarcinoma.

296 d pathway, with a smaller fraction caused by neuroendocrine tumours of the sympathetic and parasympat

297 LE as an unique vulnerability in a subset of neuroendocrine tumours, where SQLE inhibition caused a t

298 the evaluation and management of pancreatic neuroendocrine tumours.

299 mmon human and canine functioning pancreatic neuroendocrine tumours.

300 cancer (SCLC) is a recalcitrant, aggressive neuroendocrine-type cancer for which little change to fi

301 he fourth is a previously undescribed ASCL1+ neuroendocrine variant (NEv2, or SCLC-A2).